Zealand pharma Archives

Boehringer Ingelheim Zealand Pharma diabetes

News and Trends 23 Aug 2017

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […]

August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 9 Aug 2017

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 10 Jul 2017

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […]

July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 18 Jan 2017

New Combo Therapy for Type 2 Diabetes to Sweep Europe

Zealand Pharma and its partner Sanofi have made it to the European market with a new combination therapy to treat type 2 diabetes. Suliqua, a treatment for type 2 diabetes, has received marketing authorization in Europe. This feat has earned Zealand Pharma a €9.4M ($10M) payment from its partner Sanofi. The big pharma is responsible […]

January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

copenhagen biothec genmab symphogen zealand

Best in Biotech 3 May 2016

Here are 12 Biotechs you need to know in Copenhagen – Skål!

With its canals, the Little Mermaid and the oldest amusement park in the world, Copenhagen is at the heart of the world’s obsession with Scandinavia – and it has a biotech scene to match. Pharma and biotech play a strong role in Denmark’s economy. The country is home to some key companies in the field, including […]

May 3, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 11 Dec 2015

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

This week we say farewell to Zurich and head North, through Germany where we arrive at our next destination, the capital city of Denmark, Copenhagen. This amazing city is famous for the Little Mermaid Statue, the autonomous neighborhood of Christiania and Tivoli Gardens Amusement Park. It is also home to our biotech of the week: Zealand […]

December 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Zealand pharma

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

New Combo Therapy for Type 2 Diabetes to Sweep Europe

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Here are 12 Biotechs you need to know in Copenhagen – Skål!

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!